Introduction {#s1}
============

With the increasing understanding of cellular diversity and plasticity at the single cell-resolution, knowledge of the mesenchyme still lags behind the epithelium. *Pdgfra* is expressed in selected cell types in a wide array of mesenchymal tissues, including the lung, heart, intestine, skin and cranial facial mesenchyme ([@bib5]; [@bib10]; [@bib18]; [@bib19]; [@bib25]; [@bib26]). In accordance, *Pdgfra*-null mice die at mid-gestation with failed development of multiple mesenchymal tissues ([@bib42]). Conditional inactivation of *Pdgfra* in the lung mesenchyme at a later time during embryogenesis led to simplified alveoli, suggesting that it is essential for septal ridge formation ([@bib7]; [@bib28]). In the adult lungs, *Pdgfra^+^* cells have been described to be in close proximity to alveolar epithelial type 2 cells (AEC2s), and are implicated as niche for AEC2s by way of supporting their proliferation and differentiation ([@bib2]). Recent studies further defined the *Pdgfra+* cells as niche for the subset of AEC2s that are especially primed as progenitors in repair ([@bib31]; [@bib46]). Aberrant PDGFRA activity have been linked to a large number of diseases, including adult diseases such as fibrosis and cancer, and pediatric diseases such as bronchopulmonary dysplasia (BPD) ([@bib11]; [@bib30]; [@bib32]; [@bib35]; [@bib38]). These data support that *Pdgfra^+^* cells and PDGFRA function in these cells are of key importance in the development, homeostasis and pathogenesis of the mesenchyme.

In the lungs, the term 'myofibroblasts' has been used to define alveolar cells that express smooth muscle markers such as alpha-smooth muscle actin (a-SMA, encoded by *Actin alpha two* or *Acta2* gene), or smooth muscle 22a (SM22a, encoded by *Transgelin* or *Tagln* gene). While lung myofibroblasts most commonly referred to cells in patients with adult diseases such as fibrosis, smooth muscle marker-positive alveolar cells are also found in patients with prematurity related neonatal diseases such as bronchopulmonary dysplasia. Moreover, they are found in normal lungs during maturation. In normal mouse lungs, myofibroblasts are mostly found in the neonatal period, between postnatal day (P) three and P13, in the first phase of alveologenesis ([@bib7]; [@bib27]). After P14, a-SMA and SM22a expression in the alveolar region is drastically reduced to near baseline levels, continuing into the adult. Thus, in the normal lung, the term 'myofibroblasts' refers to the population of cells that are transiently expressing a-SMA+ and SM22a+ during the process of alveologenesis when secondary septae or crests form. For this reason, they have also been referred to as secondary crest myofibroblasts ([@bib23]). However, in pathological settings, such as in BPD and neonatal hyperoxia mouse model of BPD, smooth muscle markers continue to be detected in the alveolar region, indicating persistence of myofibroblasts. In the adult lung fibrosis and bleomycin mouse model of fibrosis, smooth muscle markers return in the alveolar region, either from re-expression of these markers in cells that used to express them, or from de novo expression in cells that were never myofibroblasts. The cellular relationship as well as molecular similarities among these three types of myofibroblasts have not been defined. Understanding the mechanisms underlying the dynamic nature of normal myofibroblasts may inform how we can convert fibrotic myofibroblasts into non-fibrotic lung mesenchymal cells.

In the normal lungs during alveologenesis, using a BAC transgenic *Pdgfra-creERT2* line in lineage tracing, it was reported that *Pdgfra*+ cells give rise to both myofibroblasts and lipofibroblasts, with a slight bias towards more lipofibroblasts ([@bib33]). At this early postnatal stage, myofibroblasts are found to underline nascent septal ridges, suggesting that they may be important for septae formation ([@bib7]). They also deposit extracellular matrix, such as elastin, which provides the lungs with its elasticity and tensile strength ([@bib44]). In comparison, lipofibroblasts are characterized by their lipid-filled vesicles, and expression of markers such as Perilipin 2 (PLIN2, also known as ADRP). In addition to *Pdgfra*+ cells, it has also been shown that *Tbx4* and *FGF10* expressing cells of the distal lung can give rise to lipofibroblasts during development ([@bib13]; [@bib47]). In the adult lungs, using the BAC transgenic *Pdgfra-creERT2* line, it was shown that lineaged cells do contribute to fibrotic myofibroblasts ([@bib46]). In addition, other cell lineages, for example, *Adrp*-expressing lipofibroblasts can also contribute to fibrotic myofibroblasts ([@bib14]).

In this study, we addressed the relationship between *Pdgfra*+ cells and the three types of myofibroblasts by generating a novel *Pdgfra^rtTA^* knockin mouse line using CRISPR/Cas9 technology. This line faithfully labeled *Pdgfra*-expressing cells. In normal development, we found that *Pdgfra*+ cells give rise primarily to alveolar myofibroblasts and very few lipofibroblasts, counter to previous report ([@bib33]). In the two models of lung diseases, *Pdgfra*+ cells showed substantial contribution to myofibroblasts in the bleomycin model of fibrosis, but not in the hyperoxia model of BPD. These findings demonstrate that the *Pdgfra*+ cells have distinct lineage potential in different settings, and make distinct contribution to the three types of myofibroblasts.

Results {#s2}
=======

Efficient generation of the *Pdgfra^rtTA^* knockin line using CRISPR/Cas9 {#s2-1}
-------------------------------------------------------------------------

To generate *Pdgfra^rtTA^* line, we used the CRISPR/Cas9 technology and designed a guide RNA (gRNA) targeting a site in the first intron of *Pdgfra*. This is the same insertion site as in the *Pdgfra^GFP^* line, which is frequently used as a reporter of *Pdgfra* expression ([@bib9]; [@bib16]; [@bib17]; [@bib28]; [@bib29]). We chose to generate an rtTA knockin line rather than a creERT2 knockin line for two reasons. First, rtTA is activated by doxycycline which does not induce the frequent abortion observed with prenatal administration of tamoxifen that is needed to induce creERT2. Second, rtTA can be used to turn on/off transgene expression dynamically, while creERT2 acts through DNA re-arrangements that are not reversible. A double-stranded donor plasmid was generated that contains a splicing acceptor (SA), rtTA and triple polyadenylation sequence (3 PA), with \~1.5 kb homologous arms on each side ([Figure 1A](#fig1){ref-type="fig"}). Coinjection of CAS9 protein, gRNA and donor plasmid yielded 23 pups. Among them, two had the identical correct rtTA insertion through homologous recombination. Initial characterization indicated that the two lines behaved similarly. Thus, we used one of the two lines for all following experiments ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}).

![Generation and characterization of *Pdgfra^rtTA^* knock-in mouse line using CRISPR/Cas9.\
(**A**) A schematic overview of the strategy for generating the *Pdgfra^rtTA^* knock-in allele. The gRNA coding sequence is as shown, and the protospacer-adjacent motif (PAM) sequence is indicated in green. The first three of *Pdgfra* exons are diagramed in blue. The SA-rtTA-3PA fragment is diagramed in red. The homologous arms of the donor vector are indicated as HA-L (\~1.5 kb) and HA-R (\~1.5 kb). The approximate positions of primers used for PCR analysis are shown (LF-left forward, LB-left back, RF-right forward, RB-right back). (**B**) Representative immunofluorescent staining showing GFP+ cells in *Pdgfra^rtTA^;tetO-GFP* mice and *Pdgfra^GFP^* mice at P7, scale bars: 50 µm. (**C**) Quantification of the percentage of GFP+ cells as compared to total cell number in the lungs of the two different strains as shown in B (14.66 ± 1.04 for *Pdgfra^rtTA^;tetO-GFP* mice and 16.33 ± 1.34 for *Pdgfra^GFP^* mice, ns for not significant, p=0.379, n = 3 each). (**D**) FACS analysis of GFP+ cells in *Pdgfra^rtTA^;tetO-GFP* mice and *Pdgfra^GFP^* mice as indicated at P7. (**E**) Quantification of the percentage of GFP+ cells as compared to total cell number in the lungs of the two different strains as shown in D (2.07 ± 0.15 for *Pdgfra^rtTA^;tetO-GFP* mice and 3.48 ± 0.64 for *Pdgfra^GFP^* mice, ns for not significant, p=0.0759, n = 4 each).\
10.7554/eLife.36865.005Figure 1---source data 1.Raw data for [Figure 1](#fig1){ref-type="fig"}.](elife-36865-fig1){#fig1}

*PDGFRa^rtTA^* drives rtTA activity faithfully in the *Pdgfra* expression pattern {#s2-2}
---------------------------------------------------------------------------------

To determine rtTA activity, we mated *Pdgfra^rtTA^* mice with *tetO-GFP* reporter mice. Doxycycline (dox) administration started at embryonic day (E) 9.5 and continued on to postnatal day (P) 7, the peak of alveologenesis, when the activity was analyzed. In sections of the alveolar region, GFP signal was found regularly at septal tips ([Figure 1B](#fig1){ref-type="fig"}). This pattern replicates that of the *Pdgfra^GFP^* line. Quantification across sections from multiple lung samples showed that GFP+ cells made up a similar percentage of total alveolar cell population in *Pdgfra^rtTA^;tetO-GFP* lungs as compared to *Pdgfra^GFP^* lungs ([Figure 1C](#fig1){ref-type="fig"}). Quantification using flow cytometry analysis from dissociated lungs revealed that GFP+ cells made up a smaller percentage of total lung cells in *Pdgfra^rtTA^;tetO-GFP* lungs as compared to *Pdgfra^GFP^* lungs, but the difference is not statistically significant ([Figure 1D,E](#fig1){ref-type="fig"}). For labeling efficiency in *Pdgfra^rtTA^;tetO-GFP*, flow cytometry analysis showed that out of the total PDGFRa+ cells as labeled by anti-CD140a (PDGFRa)-PE antibody, 78.62 ± 5.71% were GFP+ ([Figure 1---figure supplement 1C,D](#fig1s1){ref-type="fig"}). These results indicate that the knockin rtTA strain recapitulates *Pdgfra* expression efficiently.

Lineage tracing revealed that *Pdgfra* cells give rise primarily to normal alveolar myofibroblasts {#s2-3}
--------------------------------------------------------------------------------------------------

To perform lineage tracing of *Pdgfra*-expressing cells, we generated *Pdgfra^rtTA^;tetO-cre;Rosa-tdTomato* reporter mice. First, with no dox treatment, only rare tdTomato+ cells were observed, suggesting that there is very little leaky activity ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Second, when induced with dox starting at E9.5 and analyzed at E12.5, *Pdgfra*+ lineaged cells represent a large proportion of mesenchymal cells, similar to that of GFP+ cells in E12.5 *Pdgfra^GFP^* lungs ([Figure 2---figure supplement 1B,B', C and C'](#fig2s1){ref-type="fig"}). However, there are unlabeled mesenchymal cells in lungs of both strains.

Third, when induced with dox starting at E9.5 and continuing on to P7, the peak of alveologenesis, tdTomato +*Pdgfra* lineaged cells were primarily located at the septal tips ([Figure 2A](#fig2){ref-type="fig"}). TdTomato signal showed substantial colocalization with myofibroblast marker SM22a staining in the alveolar region ([Figure 2B--E](#fig2){ref-type="fig"}, arrows). A similar colocalization was observed with another myofibroblasts marker, a-SMA ([Figure 2---figure supplement 1D--F](#fig2s1){ref-type="fig"}). Quantification revealed that 94.3 ± 1.83% of tdTomato+ cells were SM22a-positive ([Figure 2N](#fig2){ref-type="fig"}). In comparison, only 5.6 ± 1.19% of tdTomato+ cells were positive for the lipofibroblast marker ADRP ([Figure 2F--I](#fig2){ref-type="fig"} and [Figure 2N](#fig2){ref-type="fig"}). Interestingly, 3.78 ± 1.48% of tdTomato+ cells were positive for the endothelial marker EGR ([Figure 2J--M](#fig2){ref-type="fig"} and [Figure 2N](#fig2){ref-type="fig"}). This was also confirmed with ICAM2 staining, a second marker of endothelial cells ([Figure 2---figure supplement 1G--I](#fig2s1){ref-type="fig"}). Focusing on myofibroblasts, quantification revealed that 92.71 ± 0.84% of SM22a + cells were tdTomato+ ([Figure 2O](#fig2){ref-type="fig"}), indicating that the majority of the myofibroblasts at P7 are derived from *Pdgfra*+ cells. There was no labeling of the vascular smooth muscles at P7 ([Figure 2---figure supplement 1J--L](#fig2s1){ref-type="fig"}). While there were labeled cells subjacent to the airway, they did not overlap with airway smooth muscles upon close inspection ([Figure 2---figure supplement 1J--L](#fig2s1){ref-type="fig"}).

![Lineage tracing of *Pdgfra* cells starting prenatally.\
(**A**) Timeline of the start of dox treatment and analysis. (**B--M**) Representative immunofluorescent staining of P7 *Pdgfra^rtTA^;tetO-cre;Rosa-tdTomato* lungs. Markers are as indicated: tdTomato (red), the myofibroblast marker SM22a (green) and DAPI (blue) (**B--E**); the lipofibroblast marker ADRP (green) (**F--I**); the endothelium cells marker ERG (green) (**J--M**). Arrows in panels E, I and M indicate cells with co-localization of signals. Scale bars: 50 µm. (**N**) Quantification of the percentages within tdTomato+ cells that are also SM22a+ for myofibroblasts, ADRP+ for lipofibroblasts, and ERG+ for endothelial cells, respectively (94.3 ± 1.83 for SM22a, 5.6 ± 1.19 for ADRP and 3.78 ± 1.48 for ERG, n = 3 each). (**O**) Quantification of the percentage within SM22a+ cells that are also tdTomato+ for lineaged cells (92.71 ± 0.84, n = 3).\
10.7554/eLife.36865.011Figure 2---source data 1.Raw data for [Figure 2](#fig2){ref-type="fig"}.](elife-36865-fig2){#fig2}

Fourth, we traced the postnatal lineage starting at birth by a single dose of dox injection at P0 followed by dox food until analysis at P7 ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Similar to our results from prenatal tracing, 95.57 ± 1.65% of tdTomato+ cells were positive for SM22a, and 5.25 ± 0.75% were positive for ADRP ([Figure 2---figure supplement 2B--I](#fig2s2){ref-type="fig"} and [Figure 2---figure supplement 2N](#fig2s2){ref-type="fig"}). Distinct to the result from prenatal tracing, no tdTomato+ cells were positive for ERG ([Figure 2---figure supplement 2J--M](#fig2s2){ref-type="fig"} and [Figure 2---figure supplement 2N](#fig2s2){ref-type="fig"}). Taken together, the findings from our knockin line demonstrate that *Pdgfra*-lineaged cells give rise primarily to myofibroblasts, with minor contributions to lipofibroblasts and endothelial cells.

We recently showed that in a normal lung, myofibroblasts as defined by a-SMA and SM22a expression, are transiently detected starting at P3, peaks at P7, lowers to close to undetectable levels starting at P14, continuing into adult ([@bib7]). The duration of expression corresponds precisely with the first of the two phases of alveologenesis ([@bib41]). This observation raised the question of whether the loss of myofibroblast markers is due to myofibroblast cell death or their downregulation of smooth muscle characteristics. Since *Pdgfra+* cells give rise primarily to myofibroblasts as demonstrated above, we asked whether the tdTomato+ cells simply disappeared, or survived but turned off SM22a expression. After dox induction in the early postnatal stage, tdTomato+ cells were found to survive to adult stage as analyzed at P40, even though very little SM22a or ADRP expression can be detected ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). These data suggest that the transient nature of myofibroblasts during alveologenesis is due to these cells turning on and off smooth muscle markers.

Single cell transcriptome analysis of *Pdgfra*+ cells revealed diversity during alveologenesis {#s2-4}
----------------------------------------------------------------------------------------------

To further characterize *Pdgfra*+ cells during alveologensis, we performed single-cell RNA sequencing (scRNA-Seq) using fluorescence-activated cell sorting (FACS) enriched GFP+ cells from *Pdgfra^GFP^* lungs at P7 ([Figure 1D](#fig1){ref-type="fig"}) and P15 ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). For P7, we analyzed profiles of 3204 sorted cells, with a median of 1596 genes per cell. t-distributed stochastic neighbor embedding (tSNE)-based plot revealed that *Pdgfra*+ cells from P7 lungs can be separated into five clusters ([Figure 3A](#fig3){ref-type="fig"}). Marker gene expression showed that the large cluster one contained the majority of *Pdgfra-*high expression cells, while the large cluster two contained the majority of *Pdgfra-*low expression cells. Interestingly, cluster two exhibited enriched expression of *Fgf10* and *Wnt2* ([Figure 3B,C](#fig3){ref-type="fig"}). Consistent with prior publication that *Fgf10* lineaged cells give rise to lipofibroblasts ([@bib13]), cluster two contains cells that express *Plin2*, a lipofibroblast marker. Cluster three exhibited enriched expression of genes associated with cell cycle and cell proliferation, such as *Cks2* and *Top2a* ([Figure 3B](#fig3){ref-type="fig"}). Cluster 4, a distinct small population of cells, expressed *Lgr6*, which is primarily associated with airway smooth muscle cells ([@bib22]) ([Figure 3B,C](#fig3){ref-type="fig"}). Consistent with our finding that *Pdgfra*+ cells do not contribute to airway smooth muscles, close examination indicated that cluster 4 cells showed no or low *Pdgfra* expression, suggesting that this small population may have come through GFP+ sorting as escapers from FACS gating. Finally, cluster 5, a distinct small population, exhibited expression enriched in matrix associated genes, including *Decorin* (*Dcn*) and several collagen genes (*Col1a1*, *Col3a1* and *Col14a1*) ([Figure 3B,C](#fig3){ref-type="fig"}). Focusing on myofibroblasts and lipofibroblasts, data from scRNAseq suggest that the majority of *Pdgfra*+ cells express *Acta2* and *Tagln*, while a minority of them express *Plin2* ([Figure 3C](#fig3){ref-type="fig"}), consistent with our lineage tracing data.

![Single cell transcriptome analysis of *Pdgfra*+ cells during alveologenesis.\
(**A, D**) tSNE plots of scRNAseq data from cells isolated from P7 (**A**) and P15 (**D**) *Pdgfra^GFP^* lungs. Cells can be clustered into five and four main distinct populations at P7 and P15, respectively. Circles in D highlight satellite clusters. (**B, E**) Heatmap showing top expressed genes across clusters from P7 (**B**) and P15 (**E**) *Pdgfra^GFP^* lungs. (**C, F**) Distribution of cells expressing the indicated marker genes on tSNE plots from P7 (**C**) and P15 (**F**) *Pdgfra^GFP^* lungs. (**G**) A list of representative genes showed altered expression in P7 versus P15 *Pdgfra^GFP^* lungs, as indicated by the average unique molecular identifier (UMI) of the gene per cell in the *Pdgfra*-high clusters (for *Acta2*, *Actg2*, *Tagln* and *Myh11*), or in the matrix clusters (for *Dcn*, *Col1a1*).](elife-36865-fig3){#fig3}

For P15 *Pdgfra^GFP^* lungs, we were able to profile 1,234 cells with a median of 1441 genes per cell. tSNE-based plot revealed that these cells can be separated into four main clusters with a few satellite groups ([Figure 3D](#fig3){ref-type="fig"}). There are similarities and differences as compared to P7. Cluster one at P15, similar as cluster one at P7, contained a majority of *Pdgfra-*high expressing cells ([Figure 3E,F](#fig3){ref-type="fig"}). While they still express myofibroblast markers such as *Acta2* and *Tagln*, their level, as well as the level of other myofibroblast-associated genes, are significantly lower at P15 compared to P7 ([Figure 3G](#fig3){ref-type="fig"}), consistent with our finding from antibody staining. Cluster 2, similar to cluster two at P7, exhibited enriched expression of *Fgf10* and to a less extent *Wnt2* and *Plin2* ([Figure 3E,F](#fig3){ref-type="fig"}). At P15, we did not detect a cluster equivalent to cluster three at P7, the cluster with cell cycle and cell proliferating gene signature. This is in line with published finding that Ki67, a proliferation marker, correlates with *Pdgfra* expression at P4, but not at P12 ([@bib20]). The P15 cluster three was enriched for cells expressing *Lgr6*, and thereby is similar to cluster four in P7 lungs, with primarily airway smooth muscle cell characteristics ([Figure 3E,F](#fig3){ref-type="fig"}). The P15 cluster four exhibited enriched expression of matrix associated genes, some of them the same as cluster five markers in P7 lungs, suggesting that there is a small subset of the *Pdgfra*-low population that continued to express matrix-associated genes at a high level ([Figure 3E--G](#fig3){ref-type="fig"}). At P15 but not at P7, there are several scattered satellite small populations (circled) that are *Pdgfra*-negative, and are positive for *Ptprc* (CD45) and enriched for immune markers ([Figure 3A,C,D,F](#fig3){ref-type="fig"}). They are likely immune cells that escaped FACS gating.

Genetic ablation of *Pdgfra*+ cells leads to simplified alveoli {#s2-5}
---------------------------------------------------------------

Data from us and others have shown that the *Pdgfra*+ myofibroblasts underline the septal ridges during alveologenesis ([@bib7]; [@bib15]; [@bib27]), raising the hypothesis that *Pdgfra*+ myofibroblasts may be essential for septae formation. To test this directly, we genetically ablated *Pdgfra*+ cells in *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* mice. Neonatal triple transgenic mice received three daily injections of dox at P3-P5 to induce DTA expression at the onset of alveologenesis. The pups were harvested at P15 ([Figure 4A](#fig4){ref-type="fig"}). After dox induction, qRT-PCR result showed that *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* lungs exhibited a 58% reduction of *Pdgfra* transcripts compared to controls, indicating the efficiency of ablation ([Figure 4B](#fig4){ref-type="fig"}). This ablation led to a clear emphysema-like enlargement of distal airspaces, a 57% increase as quantified by MLI as compared to control ([Figure 4C,D,I](#fig4){ref-type="fig"}). This is accompanied by disorganized Elastin, the key extracellular matrix molecule deposited by myofibroblasts ([Figure 4E,F](#fig4){ref-type="fig"}). *Pdgfra*+ cells have been described as niche for AEC2s by way of supporting their proliferation and differentiation ([@bib2]). While there is a decrease of AEC2 cells in the lungs after *Pdgfra*+ cell loss, there is no change in the % AEC2 cells to total, suggesting that the observed AEC2 reduction is proportion to the overall reduction of total cell number due to simplification ([Figure 4G,H and J](#fig4){ref-type="fig"}). Overall, these findings support the conclusion that the presence of *Pdgfra*+ myofibroblasts are essential for alveologenesis.

![Genetic ablation of *Pdgfrα*+ cells led to simplified alveoli.\
(**A**) Timeline of dox treatments and analysis. (**B**) qRT-PCR analysis indicated decreased *Pdgfra* expression in *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* lungs compared to controls (1 ± 0.06 for control and 0.42 ± 0.05 for *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* mice, \*\*p=0.0019, n = 3 each). (**C--D**) Representative H and E stained sections showing that *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* mice have simplified alveoli compared to control. (**E--F**) Representative immunofluorescent stained sections for Elastin (red) and DAPI (blue) showing that *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* lungs have disorganized Elastin. (**G--H**) Representative Immunofluorescent staining for AEC2 cells marker SPC (red) and DAPI (blue) showing that *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* lungs have reduced AEC2 cells in proportion with alveoli simplification. Scale bars: 50 µm. (**I**) Quantification of alveolar simplification by MLI (1 ± 0.05 for control and 1.57 ± 0.04 for *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* mice, \*\*\*p=0.0009, n = 3 each). (**J**) Quantification of the percentage of total cells that are SPC+. There is no change in the proportion with or without ablation (14.9 ± 1.06 for control and 16.4 ± 0.93 for *Pdgfra^rtTA^;tetO-cre;Rosa-Dta* mice, ns for not significant, p=0.3414, n = 3 each).\
10.7554/eLife.36865.015Figure 4---source data 1.Raw data for [Figure 4](#fig4){ref-type="fig"}.](elife-36865-fig4){#fig4}

*PDGFRa*-lineaged cells contribute to pathological myofibroblasts in the bleomycin model of lung fibrosis {#s2-6}
---------------------------------------------------------------------------------------------------------

Multiple studies have shown that PDGF signaling plays an important role in fibrosis. Increased PDGF signaling via transgenic expression of a PDGFA ligand or conditional activation of a gain-of-function PDGFRα mutant form is sufficient to cause tissue fibrosis ([@bib35]; [@bib37]). Chemical inhibitors of PDGFRα/β tyrosine kinase activity can reduce lung fibrosis in a radiation induced fibrosis model ([@bib1]). To directly test the hypothesis that *Pdgfra* lineaged cells contribute to myofibroblasts in the context of adult pulmonary fibrosis, we carried out lineage tracing in *Pdgfra^rtTA^;tetO-cre; Rosa-tdTomato* triple transgenic mice treated with bleomycin. Mice were given one dose of dox injection one week before bleomycin injury when all alveolar *Pdgfra*+ cells were SM22-. Lungs were harvested for histology at either 14 or 21 days after bleomycin administration ([Figure 5A](#fig5){ref-type="fig"}). Compared to controls treated with PBS at the equivalent stage, we detected a significant increase in lineage-labeled tdTomato+ cells in the bleomycin group ([Figure 5B,E,H,K and N](#fig5){ref-type="fig"}). A notable subset of these lineaged cells showed proliferative marker Ki67+ in the bleomycin group, but none in the control group ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In addition, there were more lineaged cells that are SM22a+ at 21 days after bleomycin (\~45%) than at 14 days (\~26%) ([Figure 5B--M and O](#fig5){ref-type="fig"}). These results suggest that *Pdgfra*-lineaged cells increase in number and upregulate SM22a expression following bleomycin-induced injury, and contribute significantly to pathological myofibroblasts in this model of adult pulmonary fibrosis.

![*Pdgfra*-lineage cells increased and contributed to myofibroblasts following bleomycin-induced injury.\
(**A**) Timeline of dox treatment, bleomycin administration and analysis. *Pdgfra^rtTA^;tetO-cre;Rosa-tdTomato* mice were given one dose of dox injection 7 days (**D**) before bleomycin injury. Lungs were analyzed at either D14 or D21 after bleomycin administration. (**B--M**) Representative immunofluorescent staining for tdTomato (red), SM22a (green) and DAPI (blue) in lungs of PBS-treated controls at D14 (**B--D**), bleomycin-treated mice at D14 (**E--G**), PBS-treated controls at D21 (**H--J**), and bleomycin-treated mice at D21 (**K--M**). (**N**) Quantification of the mean percentage of tdTomato+ cells in total (10.14 ± 1.08 for PBS, 20.4 ± 1.75 for bleomycin D14 and 42.93 ± 2.39 for bleomycin D21. PBS versus bleomycin D14, \*\*p=0.0025; PBS versus bleomycin D21, \*\*\*\*p=0.000016; bleomycin D14 versus bleomycin D21, \*\*\*p=0.0003; *n* = 4 each). (**O**) Quantification of the mean percentage of SM22a + cells in tdTomato+ cells (26.85 ± 2.85 for bleomycin D14 and 45.01 ± 4.1 for bleomycin D21, \*p=0.0109, *n* = 4 each). Scale bars: 50 µm.\
10.7554/eLife.36865.018Figure 5---source data 1.Raw data for [Figure 5](#fig5){ref-type="fig"}.](elife-36865-fig5){#fig5}

*Pdgfra*-lineaged cells are decreased following neonatal hyperoxia and are not a major contributor to persisting myofibroblasts {#s2-7}
-------------------------------------------------------------------------------------------------------------------------------

It has been shown that pathological myofibroblasts increase and persist in both human BPD lungs as well as neonatal hyperoxia model of BPD ([@bib3]; [@bib6]; [@bib7]; [@bib38]). To determine if *Pdgfra*-lineaged cells contribute to pathological myofibroblasts in the neonatal hyperoxia model of BPD, we examined lineaged cells in *Pdgfra^rtTA^;tetO-cre;Rosa-tdTomato* triple transgenic mice following treatment. Pregnant females were fed dox food until P0, when the females and their pups were switched to normal food that do not contain dox, and raised in 75% O2 until analysis at P12 ([Figure 6A](#fig6){ref-type="fig"}). As expected, compared to room air controls, exposure to 75% O2 resulted in simplified alveoli, and a persistence of high SM22a staining at P12 when SM22a staining is already low in room air control lungs ([Figure 6B--G](#fig6){ref-type="fig"}). In contrast to the increase of lineaged cells following bleomycin injury, neonatal hyperoxia led to a statistically significant decrease in the tdTomato+ *Pdgfra*-lineaged cells ([Figure 6B--D](#fig6){ref-type="fig"}). As a consequence, few of the high SM22a+ cells showed tdTomato lineage marker ([Figure 6F](#fig6){ref-type="fig"}). A previous in vitro study showed that hyperoxia treatment of cultured lung mesenchymal cells lead to an increase of myofibroblasts and concomitant decrease of lipofibroblasts ([@bib39]). Consistent with this, we found a statistically significant decrease of lipofibroblast marker ADRP in neonatal hyperoxia treated lungs ([Figure 6H--J](#fig6){ref-type="fig"}), raising the possibility that a possible lipofibroblasts to myofibroblasts transdifferentiation may account for the decrease in the former and the increase in the latter cell type. Taken together, our findings indicate that *Pdgfra*-lineaged cells contribute significantly to pathological myofibroblasts in the bleomycin model of lung fibrosis, but not in the neonatal hyperoxia model of BPD.

![*Pdgfra*-lineaged cells decrease following neonatal hyperoxia-induced injury.\
(**A**) Timeline of dox and hyperoxia treatment. Pregnant females were fed dox food between E9.5 and P0. Pups and mother were then fed food without dox, raised in 75% O2 or room air from P0 to P12 and the lungs were harvested at P12. (**B, C**) Representative immunofluorescent staining for tdTomato (red) and DAPI (blue) showing that the hyperoxia group have decreased tdTomato-lineaged cells compared to room air controls. (**D**) Quantification showing the percentage of tdTomato+ cells in room air and hyperoxia (17.6 ± 1.37 for room air and 7.25 ± 0.65 for hyperoxia, \*\*p=0.0024, n = 3 each). (**E, F**) Representative immunofluorescent staining for tdTomato (red), SM22a (green) and DAPI (blue) showing that the hyperoxia group have increased SM22a+ myofibroblasts. (**G**) Quantification showing relative SM22a staining intensity as quantified in relationship to DAPI intensity (1 ± 0.11 for room air and 1.62 ± 0.17 for hyperoxia, \*p=0.0342, n = 3 each). (**H, I**) Representative immunofluorescent staining for tdTomato (red), ADRP (green) and DAPI (blue) showing that the hyperoxia group have decreased ADRP+ lipofibroblasts. (**J**) Quantification showing relative ADRP staining intensity as quantified in relationship to DAPI intensity (1 ± 0.04 for room air and 0.74 ± 0.06 for hyperoxia, \*p=0.0257, n = 3 each). Scale bars: 50 µm.\
10.7554/eLife.36865.020Figure 6---source data 1.Raw data for [Figure 6](#fig6){ref-type="fig"}.](elife-36865-fig6){#fig6}

Discussion {#s3}
==========

To address the origin and plasticity of tissue mesenchymal cell types, we focused on *Pdgfra*, which has been extensively implicated as a marker of progenitors and/or progenitor niches in normal development and disease pathogenesis ([@bib16]; [@bib28]; [@bib40]; [@bib46]). Using the novel knockin *Pdgfra^rtTA^* line, we were able to precisely capture *Pdgfra* expression and rigorously interrogate the in vivo lineage of these cells. Our findings using this line revealed that these cells show distinct potential in giving rise to the different types of myofibroblasts through development and pathogenesis ([Figure 7](#fig7){ref-type="fig"}).

![A model illustrating the lineage potential of *Pdgfra*-lineaged cells in development and pathogenesis.\
In normal development (black notes), *Pdgfra*-lineaged cells give rise primarily to myofibroblasts, and minimally to lipofibroblasts and endothelial cells. In pathogenesis (blue notes), *Pdgfra*-lineaged cells contribute substantially to myofibroblasts in the bleomycin model of fibrosis, but contribute minimally to myofibroblasts in the neonatal hyperoxia model of BPD. Black and blue arrows are weighted to indicate distinct extent of contribution.](elife-36865-fig7){#fig7}

Lineage tracing during development showed that shortly after birth as the lung enters into the alveologenesis program to build new gas-exchange surface area (P3-P14), *Pdgfra*+ cells primarily (\~95%) give rise to myofibroblasts, with minor (\~5%) contribution to lipofibroblasts. This differs from the results from a recent lineage tracing study using a *Pdgfra-CreERT2* BAC transgenic line, which showed that lineaged cells gave rise to more lipofibroblasts than myofibroblasts at the same stage (P7) ([@bib33]). The difference of the results may be due to differences in the cell populations that are captured by the knock-in line versus the transgenic line. Despite being a BAC transgenic line, it may not recapitulate endogenous *Pdgfra* expression because it may be missing some required remote regulatory sequences, or it may be influenced by enhancers near the random transgenic insertion site. Conversely, the difference could be due to that our *Pdgfra^rtTA^* knockin line is missing one copy of *Pdgfra* and thereby deficient in some aspects of lineage contribution. However, there is no notable phenotype in the *Pdgfra* heterozygotes to indicate haploinsufficiency. In addition, conditional *Pdgfra* loss-of-function mutants show decreased myofibroblasts and maintenance of lipofibroblasts ([@bib28]). Thus, if there is any undetected happloinsufficiency in our *Pdgfra^rtTA^* knockin line, the prediction would be a lower lineage contribution to myofibroblasts compared to the BAC transgenic line, opposite to the data shown. Interestingly, \~4% of *Pdgfra*+ cells give rise to pulmonary endothelial cells in prenatal tracing but not in postnatal tracing. This is consistent with previous result showing that lung endothelial cells can be labeled by *Tbx4-rtTA* lineage tracing in the early stages but not late stages of development ([@bib47]).

Using our knockin line, lineage tracing into the early adult at P40 showed that *Pdgfra*-lineaged cells persist. However, they no longer express myofibroblast markers, since a vast majority of lung mesenchymal cells has turned down myofibroblast and lipofibroblast marker expression. Short of the identification of a differentiation marker that distinguished them from others, it appears that the *Pdgfra*+ cells may have de-differentiated to a non-descriptive, resting mesenchymal cell state. This dynamic change of cellular characteristics is distinct from the behavior of epithelial cells, where differentiated cells rarely de-differentiate unless following severe injury ([@bib36]).

Our scRNAseq data are consistent with lineage tracing data, and further add to the resolution of sub-populations within *Pdgfra*+ cells. At P7, a majority of the *Pdgfra*+ cells expressed myofibroblast markers while a minority expressed lipofibroblast marker. Cluster 1, with higher density of *Pdgfra*+ cells, are more enriched for myofibroblast markers. In comparison, cluster 2, with lower density of *Pdgfra*+ cells, are more enriched for lipofibroblast markers. This result is consistent with prior finding from the McGowan group showing that the *Pdgfra*-high cells have myofibroblast characteristics, while the Pdgfra-low cells have lipofibroblast characteristics. Comparing P15 to P7, the cluster with cell proliferation signature disappeared and the expression of myofibroblast markers are much reduced, consistent with prior findings ([@bib7]; [@bib20]). One cluster that persisted at both stages is enriched for matrix-associated genes. It remains to be determined how this population compares to the previously described matrix-fibroblasts from the adult lung, as distinct matrix markers are displayed ([@bib16]). Regardless, it is of interest that during the two phases of alveologenesis as represented by P7 and P15, there remains a small *Pdgfra*+ subpopulation that shows enriched matrix gene expression.

Data from the fibrosis model indicate that the adult *Pdgfra^+^* cells, while having lost their myofibroblast marker expression, are still capable of becoming myofibroblasts by turning on SM22a expression under injury. They also retained the ability to proliferate, which led to population expansion after injury ([@bib40]; [@bib46]). These *Pdgfra*-lineaged cells are not the only source of pathological myofibroblasts in fibrosis. For example, a recent study showed that *Plin2*-lineaged lipofibroblasts can also give rise to a-SMA+ cells in fibrosis ([@bib14]).

In contrast to the fibrosis model, in the neonatal hyperoxia model of BPD, our data showed that the *Pdgfra*-lineaged cells do not contribute significantly to myofibroblasts. This is unexpected as neonatal hyperoxia treatment occurred at the early postnatal stage when the *Pdgfra*+ cells normally contribute to myofibroblasts. Our findings showed that under hyperoxia, however, a majority of lineaged cells were lost, presumably through cell death, thereby unable to contribute to myofibroblasts. Yet, other cells differentiate into myofibroblasts. The result that lipofibroblasts were reduced in number, coupled with in vitro data that hyperoxia can drive cultured lung mesenchymal cells to preferentially adopt myofibroblast fate instead of lipofibroblast fate, raised the possibility that the lipofibroblasts may transdifferentiate into myofibroblasts in the neonatal hyperoxia model ([@bib39]). This possibility remains to be tested through lineage tracing of lipofibroblasts. Recently, a *Plin2* (*Adrp*)*^creERT2^* line was generated to label lipofibroblasts ([@bib14]; [@bib34]). However, it also labels a number of other cell types in the lung ([@bib14]). Thus, generation of a genetic tool that specifically labels lipofibroblasts will be critical to address the potential of these cells in development and injury.

Considering the three types of myofibroblasts in lung: the normal secondary crest myofibroblasts, adult fibrotic myofibroblasts, and BPD myofibroblasts, our data substantiate the notion that not all myofibroblasts are created equal. In terms of their origins, they have different contributions from *Pdgfra*-lineaged cells. Furthermore, our data support that the smooth muscle marker positive state may be a transient characteristic rather than a stable cell fate ([Figure 7](#fig7){ref-type="fig"}). This transient nature is not only a feature in development, but it also occurs in disease settings. For example, in fibrosis model, it has been shown that a-SMA+ cells can revert to lipofibroblasts, which contributes to resolution of the disease ([@bib14]).

A number of recent studies have used transcriptome, lineage tracing and epithelium-mesenchyme organoid approaches to determine the complexity of the lung mesenchyme ([@bib15]; [@bib21]; [@bib22]; [@bib23]; [@bib46]). For examples, genes that are WNT reporters such as *Lgr5*, *Lgr6*, and *Axin2*, or HH reporter such as *Gli1* have been used to lineage trace cell fate in the mesenchyme in both baseline as well as in injury settings. A next challenge is to compare the different lineaged populations to define the similarities and differences, and be able to comprehensively illustrate the complexity of the mesenchyme.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------
  REAGENT or\       Designation         Source                  Identifier      Additional information
  RESOURCE                                                                      
  ----------------- ------------------- ----------------------- --------------- ------------------------
  strain, strain\   *tetO-GFP,*\        Jackson Laboratories    016836          
  background\       mix background                                              
  (mouse)                                                                       

  strain, strain\   *Pdgfra^GFP^*\      Jackson Laboratories    007669          
  background\       , mix background                                            
  (mouse)                                                                       

  strain, strain\   *tetO-Cre,*\        Jackson Laboratories    006234          
  background\       B6 background                                               
  (mouse)                                                                       

  strain, strain\   *Rosa-tdTomato,*\   Jackson Laboratories    007914          
  background\       B6 background                                               
  (mouse)                                                                       

  strain, strain\   *Rosa-Dta,*\        Jackson Laboratories    006331          
  background\       mix background                                              
  (mouse)                                                                       

  Antibody          Elastin             Abcam                   ab21600,\       
                                                                1:500           

  Antibody          SM22a               Abcam                   ab14106,\       
                                                                1:200           

  Antibody          ADRP                Abcam                   ab52356,\       
                                                                1:200           

  Antibody          ERG                 Abcam                   ab92513,\       
                                                                1:200           

  Antibody          ICAM2               BD                      553325,\        
                                                                1:200           

  Antibody          Ki67                Abcam                   ab15580,\       
                                                                1:200           

  Antibody          a-SMA               Sigma                   F3777,\         
                                                                1:200           

  Antibody          goat anti\          Jackson Immuno\         111-095-144,\   
                    rabbit FITC         Research Laboratories   1:200           

  Antibody          goat anti\          Jackson Immuno\         111-165-144,\   
                    rabbit Cy3          Research Laboratories   1:200           

  Antibody          goat anti\          Jackson Immuno\         112-095-003\    
                    rat FITC            Research Laboratories   1:200           
  ------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

To generate *Pdgfra^rtTA^* knockin mouse strain, 5'-GAGACAGTAATTGAGGATCCTGG-3' was designed to target a PAM site in the first intron of the *Pdgfra* gene. A plasmid donor was constructed by ligating the splice acceptor (SA), rtTA, and a trimerized simian virus 40 polyadenylation (3 pA) ([@bib17]; [@bib47]). The homologous arms (1.5 kb each) were amplified from C57BL/6 mouse genomic DNA and added. *Pdgfra^rtTA^* mouse line was generated at the University of Wisconsin-Madison transgenic animal facility by injection of 50 ng/µl gRNA, 40 ng/µl CAS9 protein and 25 ng/µl donor plasmid. The founders were identified by PCR using primers: LF, 5'-AGCAACTAACTAAAGCATGGTC-3'; LB, 5'-GCTCAACTCCCAGCTTTTG-3'; RF, 5'-GAAATTGCATCGCATTGTCTG-3'; RB, 5'-ACTCTCATCCGTCTGAGTG-3'. Mice were housed and all experimental procedures were performed in American Association for Accreditation of Laboratory Animal Care-accredited laboratory animal facilities at the University of Wisconsin and University of California San Diego. Prenatal lung *Pdgfra^rtTA^* activity was induced by doxycycline (dox) administration starting at different gestational periods by feeding pregnant females with dox food (625 mg/kg; Test- Diet, Richmond, IN, USA). In postnatal pups and adult mice, *Pdgfra^rtTA^* activity was induced by intraperitoneal injection of dox (100 mg/kg body weight). For prenatal lineage tracing, we chose dox containing food because it is gentle on the pregnant females and effective at inducing activity. For postnatal lineage tracing, we chose dox injection followed by dox food because it showed a much higher efficiency compared to dox containing food only, presumably because the pups do not get to the dox food themselves and the dox transfer through the milk from the dam is not efficient.

Neonatal hyperoxia model of BPD {#s4-2}
-------------------------------

Hyperoxia-exposure was conducted as previously described ([@bib7]). Briefly, at P0, new born pups with their mother were placed into a chamber (BioSpherix) with circulated 75% oxygen through to P12. Control pups born at the same time were maintained at normoxia (room air) conditions for the same duration of the experiment. Mothers were swapped between normoxia and hyperoxia litters every fourth day to maintain maternal health. Lungs from both normoxia and hyperoxia groups were harvested at P12.

Bleomycin model of adult lung fibrosis {#s4-3}
--------------------------------------

Mice were anesthetized with ketamine (100 mg/kg) and xylazine (15 mg/kg) prior to delivering a single dose of intratracheal bleomycin (1 unit/kg, Teva Pharmaceutical Industries) dissolved in 50 µL of 0.9% NaCl Irrigation (Abbott Laboratories) via endotracheal intubation. Daily weight and wellness checks were performed until euthanasia at 14 or 21 days post-bleomycin.

Histology and immunofluorescence staining {#s4-4}
-----------------------------------------

For histological analysis, postnatal mouse lungs were gravity inflated and fixed overnight with 4% paraformaldehyde, and submerged in 30% sucrose at 4°C overnight. Whole lung lobes were embedded in OCT compound (Sakura) for cryo section. Sections were stained using a standard Hematoxylin and Eosin (H and E) protocol. Quantification of lung simplification was performed using the mean linear intercept (MLI) method as previously described ([@bib24]).

Immunofluorescence staining was performed following standard protocols and mounted with VECTASHIELD medium with DAPI (Vector Laboratories). Antibodies were listed in the resource table.

Quantitative RT-PCR {#s4-5}
-------------------

Total RNA was extracted from lungs using Trizol (Invitrogen) and an RNeasy Micro RNA extraction kit (Qiagen). RNA was reverse transcribed using the iScript Select cDNA Synthesis Kit (Bio-Rad). Quantitative PCR was performed using SYBR Green (Bio-Rad). Three technical and three biological replicates were performed for each gene. Primers used for qPCR are: *β-actin*-F: 5'-CGGCCAGGTCATCACTATTGGCAAC-3'; *β-actin*-R: 5'-GCCACAGGATTCCA-TACCCAAGAAG-3'; *Pdgfra*-F: 5'-TGCGGGTGGACTCTGATAATGC-3'; *Pdgfra*-R: 5'-GTGGAACTACTGGAACCTGTCTCG-3'.

Lung dissociation, flow cytometry and Single-Cell RNA-sequencing {#s4-6}
----------------------------------------------------------------

Lung lobes were separated and minced into small pieces in a conical tube containing 6 ml of 2 U/ml dispase (STEMCELL Technologies) followed by rotating incubation for 30 min at 37°C. 15 [µ]{.ul}l 10 mg/ml DNase I (Sigma) was added and cells were incubated on ice for 5 min. Cells were filtered through 40 [µ]{.ul}m strainers and centrifuged at 800 rpm for 6 min at 4°C. Cell pellet was resuspended in 1 ml of RBC lysis buffer (Abcam) and lysed for 90 s at room temperature. This was followed by slow and gentle addition of 6 ml DMEM media (GIBCO) and 500 mL of FBS (Hyclone). Cells were centrifuged at 800 rpm for 6 min at 4°C. Cell pellet was resuspended in PBS with 3% BSA (GIBCO) for further staining using CD140a (PDGFRa)-PE (eBioscience, 12-1401-81, 1:100) for flow cytometry. 4', 6-diamidino-2-phenylindole (DAPI) (Sigma) was used to eliminate dead cells. Flow sorting was performed with a FACS Aria II (BD Biosciences) and data were analyzed with FlowJo software (Tree Star, Inc.).

For Single-Cell RNA-sequencing, *Pdgfra^GFP^* mouse lungs at P7 and P15 were harvested and single cell preparations were FACS sorted as described above. The sorted cells were then processed following 10X genomics protocol. The sequencing libraries were validated and sequenced using HiSeq4000 platform. Sequencing reads were first aligned to mm10 reference using STAR V2.5.1b ([@bib12]) and then aligned to annotated transcripts, which were part of the Cell Ranger version 2.1 pipeline (<https://www.10xgenomics.com>). A customized pre-mRNA reference package was generated to capture all the intronic reads in addition to reads that are mapped to exons. Cell Ranger filtered cells by taking \>10% of the top n^th^ barcodes, where n is 1% of the expected number of cell counts being recovered ([@bib48]). The filtered gene-cell matrices, output from CellRanger, was further analyzed using the Seurat package V2.3 ([@bib8]) and R 3.4 ([@bib43]). The UMI raw counts were log-normalized for each cell to its total expression and scaled to z-scored residuals of linear models that predicts gene expression using normalized UMIs. The scaled data were used to perform dimensionality reduction with Sparsesvd V0.1 ([@bib4]), graph-based clustering and visualization with t-Distributed Stochastic Neighbor Embedding (t-SNE) ([@bib45]). Differential gene expression analysis was performed using Wilcoxon rank sum test. Heatmaps, t-SNE plots and visualization of marker expression were generated using Seurat. GEO accession number for the scRNA-seq data is GSE118555.

Quantification and statistical analysis {#s4-7}
---------------------------------------

For quantification of the number of immunofluorescence stained cells, or immunofluorescence staining intensity per field, four independent 20x fields per sample were analyzed. Sections from at least three lungs were quantified for each experimental group. *P*-values were calculated with two-tailed unpaired Student's *t*-test on Prism six software (GraphPad). Data were presented as mean ± SEM, and results were considered statistically significant if p\<0.05.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*Pdgfra* Marks a Cellular Lineage with Dynamic Contributions to Myofibroblasts in Lung Maturation and Injury Response\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Harry Dietz as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Your work carefully describes the generation and initial characterization of a new *Pdgfra^rtTA^* mouse line which you have used to assess lineage relationships in the developing and adult mouse lung. All three reviewers felt that your study had merit but noted important weakness that required additional experimental clarification. Three major issues were noted by the reviewers: 1) a better characterization of the *Pdgfra^rtTA^* mouse line as it pertains to fidelity of endogenous *Pdgfra* expression during lung development and in the adult is required and should include quantification of the number of *Pdgfra* expressing cells at the stages examined; 2) the relationship between *Pdgfra* expressing cells, as noted by the *Pdgfra^rtTA^* mouse line, and other mesenchymal populations including SM22a expressing myofibroblasts and ADRP expressing fibroblasts is important to define with additional experimentation; and 3) the need to use additional markers for myofibroblasts beyond SM22a given the variable definition of this cell type. Additional review points should also be addressed as noted.

Reviewer \#1:

This report describes the generation of a new *Pdgfra^rtTA^* line which the authors have used to perform cell lineage tracing experiments in mice. The *Pdgfra^rtTA^* mice appear to mark a similar (although not proven) subset of cells that the *Pdgfra^GFP^* knockin mice do. During development, *Pdgfra^rtTA^* mice mark a significant proportion of lung mesenchyme and depletion of *Pdgfra+* cells during alveologenesis causes an emphysema like phenotype. Hyperoxia injury causes a decrease in the number of embryonically *Pdgfra+* lineage traced cells. Conversely, bleomycin induced injury in adult animals labels a significant number of *Pdgfra+* cells that become myofibroblasts.

The paper is well written and the generation of this new animal model is an important contribution to the field. However, there are a number of questions regarding the lineage tracing studies and their interpretation:

1\) Since this is the first report of this new mouse model, additional characterization of its fidelity is warranted at each of the induction timepoints. The co-expression of the rtTA/GFP from this allele needs to be looked at more carefully including FACS analysis and additional immunohistochemistry to verify what% of total *Pdgfra+* and other cell types it marks.

2\) The lineage tracing studies are interesting but not well defined. For instance, the labeling of *Pdgfra+* cells at E9.5 could simply mark almost all lung mesenchyme/fibroblasts. If this is the case, then the interpretation of data in Figures 2 and 5 are somewhat unclear. The authors should provide an index at all of the times of dox induction (i.e. E9.5, P3, adult etc.) of what% of the total lung mesenchyme this allele marks. A comparison to a pan-mesoderm or mesenchyme marker would be helpful i.e. vimentin or something similar.

3\) In light of point 2 above, what do the authors make of the fact that SM22a and ADRP appear to mark the majority of alveolar mesenchyme at P7 (Figure 2)? In particular, ADRP seems to mark a lot of cells that are *Pdgfra-*. A better characterization of what these cells are is warranted.

4\) The data in Figure 5 and Figure 5---figure supplement 1 are interesting in that they show a significant number of *Pdgfra+* cells that proliferate in response to bleomycin injury. Are these the myofibroblasts or are they what appear to be a large number of SM22-/*Pdgfra+* lineage traced cells?

5\) The IHC data shown in Figure 5 appear to show that SM22+ cells at day 14 are unlikely to be derived from *Pdgfra-*lineage. Is this due to early vs late contribution to bleomycin triggered myofibroblasts?

6\) The cell ablation experiment in Figure 3 suggests that the loss of *Pdgfra-*derived early postnatal myofibroblasts results in alveolar simplification. While the authors note that AT2 cell numbers are reduced, the percentage to total lung cells is unchanged. It is unclear how the latter conclusion was made or whether total cell number or epithelial cells specifically, were altered.

Reviewer \#2:

Here the authors investigate the lineage potential of *Pdgfra-*expressing cells in the developing lung and the contribution of this lineage to lung injury-repair in different well-established models. By generating and analyzing a novel *Pdgfra^rtTA^;tetO-cre* knockin reporter mouse, they report that *Pdgfra-*expressing cells give rise largely to myofibroblasts with only modest generation of lipofibroblasts in the lung mesenchyme. Moreover, by using these mice to induce DTA-expression and ablate myofibroblasts postnatally, or to injure the adult lung with bleomycin, the authors demonstrate the key role of *Pdgfra-*lineage in alveolar formation and in mediating the fibrotic response, respectively. Lastly, they report no contribution of this lineage to the persistent myofibroblast population seen in neonatal hyperoxic lung injury.

This interesting and succinct paper provides both confirmatory and new insights about the fate of lineage-derived *Pdgra+* cells in different settings. The study is carefully done and relies on a more accurate knockin mouse model to investigate the *Pdgfra* lineage, which challenges some of the results previously reported using a BAC transgenic line.

Given the novelty of this mouse model and its potential importance to address relevant questions in the field, the details about the characterization of this line are relatively brief and sometimes missing. For example, they use two different regimens of Dox administration (IP and dox-containing food) but do not comment on the rationale and whether there were differences in labeling efficiency. What was the frequency of dox-independent labeling in these mice? Is labeling present in smooth muscle elsewhere in airways or large vessels? As a knockin line, *Pdgfra^rtTA^;tetO-cre* mice are haploinsufficient for *Pdgfra*. The authors should provide evidence or comment whether this may have influenced any of the results reported here, including the differences in labeling from that reported in the BAC transgene line.

The surprising and apparently paradoxical high number of myofibroblasts *Pdgfra*-lineage labeled negative in the BPD-hyperoxia model is one of the most interesting observations in the paper. The conclusion that this may have been accounted for by lipofibroblasts transdifferentiating into myofibroblasts should be explored in this model by lineage-labeling lipofibroblasts (ADRP or other relevant cre line). This will strengthen their conclusion and will offer further support to their *Pdgfra^rtTA^;tetO-cre* mouse model.

Reviewer \#3:

This manuscript by Li et al. describes the generation of a new line of mice in which rtTA is placed under the regulatory control of the endogenous *Pdgfra* promoter. This new line was validated by comparing specificity of Dox-dependent *tetO-GFP* expression with expression of a GFP reporter in lungs of *Pdgfra^GFP^* mice. Authors go on to show that *Pdgfra*-lineage cells of the embryonic lung transiently generate SM22a-immunoreactive cells in the perinatal period which then contribute to lipofibroblasts, that ablation of *Pdgfra*-expressing cells in the perinatal period leads to alveolar simplification and that *Pdgfra*-lineage cells differentially contribute to SM22a-immunoreactive cells in models of neonatal hyperoxia and adult bleomycin-induced fibrosis. Strengths of this study are the demonstration of a valuable new genetic tool to investigate the biology of *Pdgfra*-expressing cells of the lung and application of this tool to study the dynamics of lung mesoderm during development and perinatal lung maturation. A concern with this study is the broad classification of SM22a+ cells of the developing, perinatal and adult lung as myofibroblasts. Lineage tracing of *Pdgfra*-expressing cells is performed at various times of embryonic or postnatal lung maturation which complicates interpretation of data since *Pdgfra* is dynamically expressed within mesenchymal cells during these stages of lung development/maturation.

Specific concerns include:

1\) The conclusion that \".hitherto unappreciated complexity in the behavior of the *Pdgfra*-lineaged cells\" seems overstated. Previous studies by this group and others demonstrate that the molecular phenotype of lung mesoderm is dynamically regulated during development.

2\) Results subsection "Lineage tracing revealed that Pdgfra cells give rise primarily to normal alveolar myofibroblasts": "\[...\] demonstrate that in the early postnatal lung, *Pdgfra*-lineage cells give rise primarily to myofibroblasts, with minor contributions to lipofibroblasts and endothelial cells." This statement is a little misleading in that it implies that myofibroblast and lipofibroblast populations are distinct and fixed. In reality, as shown previously by this group (Branchfield et al., 2016) and nicely demonstrated in this study, these populations are dynamic and are either interchangeable or their relative populations change through \"pruning\" during early postnatal lung maturation. The authors provide evidence supporting the notion that these populations are interchangeable based upon long-term retention of lineage-labeled cells. A concern with these experiments is that all conclusions are made using immunofluorescence analysis to evaluate fibroblast phenotype in histologic sections, using a very limited repertoire of markers (SM22a). This study would be greatly improved by addition of single cell transcriptomics to determine the precise molecular phenotype of lineage-labeled cells and how this changes with postnatal lung maturation.

10.7554/eLife.36865.027

Author response

> Reviewer \#1:
>
> \[...\] 1) Since this is the first report of this new mouse model, additional characterization of its fidelity is warranted at each of the induction timepoints. The co-expression of the rtTA/GFP from this allele needs to be looked at more carefully including FACS analysis and additional immunohistochemistry to verify what% of total Pdgfra+ and other cell types it marks.

We have used flow cytometry analysis to better characterize our new mouse model. Data from flow revealed that the percentages of GFP+ cells in total lung cells are not statistically different in *Pdgfra^rtTA^;tetO-GFP* lungs as compared to *Pdgfra^GFP^* lungs (Figure 1D, E). Also, out of total PDGFRa+ cells as labeled by anti-CD140a (PDGFRa)-PE antibody in flow, 78.62% ± 5.71% were GFP+ in *Pdgfra^rtTA^;tetO-GFP* lungs, indicative of the efficiency of rtTA activation (Figure 1---figure supplement 1C, D).

> 2\) The lineage tracing studies are interesting but not well defined. For instance, the labeling of Pdgfra+ cells at E9.5 could simply mark almost all lung mesenchyme/fibroblasts. If this is the case, then the interpretation of data in Figures 2 and 5 are somewhat unclear. The authors should provide an index at all of the times of dox induction (i.e. E9.5, P3, adult etc.) of what% of the total lung mesenchyme this allele marks. A comparison to a pan-mesoderm or mesenchyme marker would be helpful i.e. vimentin or something similar.

We added analysis of *Pdgfra+* lineaged cells at E12.5 following dox induction at E9.5 (Figure 2---figure supplement 1B, B'). We tried vimentin antibody as a pan-mesenchymal marker, but it did not give distinct mesenchymal staining in our hands. Nevertheless, it is easy to distinguish mesenchyme from epithelium at E12.5. We found that labeling at E9.5 does not label all mesenchymal cells (Figure 2---figure supplement 1B, B'). A similar density of labeling is observed in E12.5 *Pdgfra^GFP^* lungs, suggesting that incomplete labeling is a feature of *Pdgfra* expression in a subset of mesenchymal cells (Figure 2---figure supplement 1C, C'). The conclusion that *Pdgfra+* cells represents a subset of the lung mesenchymal cells is also supported by data from multiple other groups that have studied this cell population at various time points (Endale et al., 2017; Ntokou et al., 2015; Zepp et al., 2017).

> 3\) In light of point 2 above, what do the authors make of the fact that SM22a and ADRP appear to mark the majority of alveolar mesenchyme at P7 (Figure 2)? In particular, ADRP seems to mark a lot of cells that are Pdgfra-. A better characterization of what these cells are is warranted.

Indeed, based on our data and prior published data from other labs, SM22a+ cells and ADRP+ cells are the two major cell types in the alveolar mesenchyme at P7. Our data showed that at P7, a majority of *Pdgfra*+ cells are myofibroblasts, rather than lipofibroblasts. For ADRP+ lipofibroblasts, previous reports showed that *Tbx4* lineage and *Fgf10* expressing cells contribute to lipofibroblasts (El Agha et al., 2014; Zhang et al., 2013). A more detailed reference to these data are added to the Introduction section.

> 4\) The data in Figure 5 and Figure 5---figure supplement 1 are interesting in that they show a significant number of Pdgfra+ cells that proliferate in response to bleomycin injury. Are these the myofibroblasts or are they what appear to be a large number of SM22-/Pdgfra+ lineage traced cells?

Based on Zepp et al. (2017), it was shown that in the bleomycin model, SMA+ myofibroblasts do express Ki67, a proliferation marker. This suggests that proliferating cells can simultaneously have myofibroblast characteristics following injury. In our *Pdgfra*-lineaged lungs, as labeling was carried out prior to injury when the *Pdgfra*+ cells are SM22-, we deduce that the *Pdgra*+ proliferating cells originated from SM22- cells. We clarified this in Results in subsection "PDGFRa-lineaged cells contribute to pathological myofibroblasts in the bleomycin model of lung fibrosis" and in the Discussion section.

> 5\) The IHC data shown in Figure 5 appear to show that SM22+ cells at day 14 are unlikely to be derived from Pdgfra-lineage. Is this due to early vs late contribution to bleomycin triggered myofibroblasts?

We added arrowheads in Figure 5G to highlight that at D14, a portion of the SM22+ cells are derived from the *Pdgfra* lineage. Quantification indicated that \~26% of SM22+ cells are from the *Pdgfra*+ (Figure 5O). This number increased to \~45% at D21.

> 6\) The cell ablation experiment in Figure 3 suggests that the loss of Pdgfra-derived early postnatal myofibroblasts results in alveolar simplification. While the authors note that AT2 cell numbers are reduced, the percentage to total lung cells is unchanged. It is unclear how the latter conclusion was made or whether total cell number or epithelial cells specifically, were altered.

The percentage was calculated by SPC+ AT2 cells in total lung cells base on DAPI staining. Total cell numbers were decreased per area as the lung is simplified. These numbers were added to revised Figure 4 (formerly Figure 3) source files.

> Reviewer \#2:
>
> \[...\] Given the novelty of this mouse model and its potential importance to address relevant questions in the field, the details about the characterization of this line are relatively brief and sometimes missing. For example, they use two different regimens of Dox administration (IP and dox-containing food) but do not comment on the rationale and whether there were differences in labeling efficiency.

For prenatal lineage tracing, we chose dox containing food because it is gentle on the pregnant females and effective at inducing activity. For postnatal lineage tracing, we chose dox injection followed by dox food because it showed a much higher efficiency compared to dox containing food only, presumably because the pups do not get to the dox food themselves and the dox transfer through the milk from the dam is not efficient. This rationale is added to Materials and methods section.

> What was the frequency of dox-independent labeling in these mice?

Very little leaky labeling without dox, and this result is added to Figure 2---figure supplement 1A.

> Is labeling present in smooth muscle elsewhere in airways or large vessels?

We did not observe labeling in the airway or vascular smooth muscles. Labeling subjacent to the airway does not overlap with airway smooth muscle upon close inspection. This result was added to Figure 2---figure supplement 1J-L.

> As a knockin line, Pdgfra^rtTA^;tetO-cre mice are haploinsufficient for Pdgfra. The authors should provide evidence or comment whether this may have influenced any of the results reported here, including the differences in labeling from that reported in the BAC transgene line.

This is an excellent point, and we added to the Discussion that this may be an additional possible distinction that may explain the difference between our data and the data from BAC transgenics. However, there is no notable phenotype in the *Pdgfra* heterozygotes to indicate haploinsufficiency. In addition, conditional *Pdgfra* loss-of-function mutants show decreased myofibroblasts and maintenance of lipofibroblasts (McGowan and McCoy, 2014). Thus, if there is any undetected haploinsufficiency, we would expect that using our *Pdgfra^rtTA^* knockin line, there should be fewer myofibroblasts labeled compared to the BAC transgenic line, opposite to what the data show.

> The surprising and apparently paradoxical high number of myofibroblasts Pdgfra-lineage labeled negative in the BPD-hyperoxia model is one of the most interesting observations in the paper. The conclusion that this may have been accounted for by lipofibroblasts transdifferentiating into myofibroblasts should be explored in this model by lineage-labeling lipofibroblasts (ADRP or other relevant cre line). This will strengthen their conclusion and will offer further support to their Pdgfra^rtTA^;tetOcre mouse model.

PLIN2 (ADRP) is the most commonly used lipofibroblast marker in lung. There is a published cre line, *Plin2 (Adrp*)^creERT2^ (El Agha et al., 2016; Ntokou et al., 2017). However, it is not specific for lipofibroblasts, and labels a number of other cell types in the lung (El Agha et al., 2016). Thus, we currently do not have the tool to specifically trace the lipofibroblast lineage. We added in Discussion that a high priority next-step is to identify markers that are specific for lipofibroblasts, and use them to generate mouse tools for lineage tracing and address the potential of lipofibroblasts in development and injury.

> Reviewer \#3:
>
> This manuscript by Li et al. describes the generation of a new line of mice in which rtTA is placed under the regulatory control of the endogenous Pdgfra promoter. This new line was validated by comparing specificity of Dox-dependent tetO-GFP expression with expression of a GFP reporter in lungs of Pdgfra^GFP^ mice. Authors go on to show that Pdgfra-lineage cells of the embryonic lung transiently generate SM22a-immunoreactive cells in the perinatal period which then contribute to lipofibroblasts, that ablation of Pdgfra-expressing cells in the perinatal period leads to alveolar simplification and that Pdgfra-lineage cells differentially contribute to SM22a-immunoreactive cells in models of neonatal hyperoxia and adult bleomycin-induced fibrosis. Strengths of this study are the demonstration of a valuable new genetic tool to investigate the biology of Pdgfra-expressing cells of the lung and application of this tool to study the dynamics of lung mesoderm during development and perinatal lung maturation. A concern with this study is the broad classification of SM22a+ cells of the developing, perinatal and adult lung as myofibroblasts. Lineage tracing of Pdgfra-expressing cells is performed at various times of embryonic or postnatal lung maturation which complicates interpretation of data since Pdgfra is dynamically expressed within mesenchymal cells during these stages of lung development/maturation.

We added analysis with a-SMA staining which substantiated the findings with SM22a (Figure 2---figure supplement 1D-F). We added in the Introduction a more specific definition of myofibobroblasts in the normal lung. Findings from our prior study (Branchfield et al., 2016) indicated that a-SMA and SM22a expression is absent in the distal mesenchyme in the prenatal lung. Their expression increases and peaks during the first phase of alveologenesis (P3-14), and then subsides to a low level afterwards and into adulthood. Thus, the term myofibroblasts in the normal lung only refers to the a-SMA+ and SM22a+ cells during alveologenesis when secondary septae/crests are added. Some have also referred to these cells as secondary crest myofibroblasts which is a more distinct term.

We performed lineage tracing at both prenatal (E9.5) and postnatal (P0) stages, and analyzed data at E12.5, P7 and P40 to best depict the dynamic nature of the *Pdgfra*+ cell population.

> Specific concerns include:
>
> 1\) The conclusion that \".hitherto unappreciated complexity in the behavior of the Pdgfra-lineaged cells\" seems overstated. Previous studies by this group and others demonstrate that the molecular phenotype of lung mesoderm is dynamically regulated during development.

We have deleted "hitherto unappreciated".

> 2\) Results subsection "Lineage tracing revealed that Pdgfra cells give rise primarily to normal alveolar myofibroblasts": "\[...\] demonstrate that in the early postnatal lung, Pdgfra-lineage cells give rise primarily to myofibroblasts, with minor contributions to lipofibroblasts and endothelial cells." This statement is a little misleading in that it implies that myofibroblast and lipofibroblast populations are distinct and fixed. In reality, as shown previously by this group (Branchfield et al., 2016) and nicely demonstrated in this study, these populations are dynamic and are either interchangeable or their relative populations change through \"pruning\" during early postnatal lung maturation. The authors provide evidence supporting the notion that these populations are interchangeable based upon long-term retention of lineage-labeled cells. A concern with these experiments is that all conclusions are made using immunofluorescence analysis to evaluate fibroblast phenotype in histologic sections, using a very limited repertoire of markers (SM22a). This study would be greatly improved by addition of single cell transcriptomics to determine the precise molecular phenotype of lineage-labeled cells and how this changes with postnatal lung maturation.

We thank the reviewer for these suggestions and have added single-cell transcriptomic data of *Pdgfra*-GFP+ cells at both P7 and P15 (new Figure 3). The scRNAseq data support our lineage tracing findings and provide further resolution of the complexity within the *Pdgfra*+ cells (see Results subsection "Single cell transcriptome analysis of *Pdgfra+* cells revealed diversity during

alveologenesis" and the Discussion section). We have also added analysis with a-SMA staining which substantiated the findings with SM22a (Figure 2---figure supplement 1D-F). By using *Pdgfra*-based lineage tracing in the normal lung starting at both prenatal and postnatal time points, we have observed labeling primarily in secondary crest myofibroblasts. The lineaged cells are not lost past alveologenesis due to pruning as suggested. They stay in the lung mesenchyme and simply turn down their SMA and SM22 expression. They do not interchange into lipofibroblast cells.
